Menu
ETF
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow2.45 M USD1.17 M USD-23.08 M USD9.36 M USD-142.69 M USD-159.47 M USD-165.70 M USD-106.81 M USD-76.16 M USD-69.14 M USD-79.04 M USD-45.52 M USD
Depreciation & Amortization384000 USD509000 USD922000 USD1.19 M USD4.09 M USD1.04 M USD612786 USD293886 USD213117 USD132451 USD62400 USD52467 USD
Stock-Based Compensation75000 USD264000 USD1.27 M USD11.57 M USD18.13 M USD10.68 M USD10.69 M USD8.66 M USD6.89 M USD17.41 M USD7.19 M USD4.24 M USD
Capital Expenditures34000 USD207073 USD2.45 M USD217040 USD61817 USD396154 USD165257 USD30962 USD
Cash Flow from Investing-355000 USD-2.22 M USD-1.60 M USD-23.91 M USD-21.50 M USD-827108 USD-1.26 M USD-584361 USD-606756 USD
Cash Flow from Financing3.15 M USD-235.21 M USD129.55 M USD80.72 M USD188.83 M USD162.79 M USD72.58 M USD137.23 M USD92.97 M USD43.30 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-142.73 M USD-159.68 M USD-168.15 M USD-107.03 M USD-76.22 M USD-69.54 M USD-79.21 M USD-45.55 M USD

TherapeuticsMD, Inc. is a specialty pharmaceutical and royalty company focused on women’s health in the United States and internationally. The company’s primary role is to develop and license differentiated therapies that address conditions associated with menopause, contraception, and related gynecologic needs. Through licensing agreements, TherapeuticsMD grants commercial rights to partners such as Mayne Pharma for products including hormone therapy and contraceptive offerings, while retaining economic interests via royalties. Its portfolio is complemented by vitamin and prenatal brands historically developed through its VitaMed business, aimed at obstetric and gynecologic practices. By concentrating on proprietary formulations and lifecycle management rather than large-scale sales infrastructure, TherapeuticsMD, Inc. positions itself as an asset-light participant in the pharmaceutical value chain, contributing specialized products to the broader women’s healthcare market.